White Papers

Our complimentary white papers draw on our primary research findings to provide you information on critical life sciences topics. Please fill out the short form accompanying each white paper in the list below. You will then be directed to links to the downloadable PDFs.

Click a title below to get access to a white paper.

If you have questions, call (919) 403-6583.

Latest White Papers

    New Digital Marketing in the US: It's Been a Long Journey, But [Most of] the Draft Guidance is Finally Here 2014

    Over the years, digital marketing and e-pharma-oriented conferences have focused on pharmaceutical and device companies’ forays into social media. These meetings show that previous lack of regulatory guidance has not hindered companies’ enthusiasm for new digital initiatives. Now that many life science companies have developed innovative platforms, dedicated teams have begun strategizing how to best leverage existing channels to target key patient — and more recently, physician — audiences. As companies continue to familiarize themselves with an array of social media platforms, the FDA has initiated steps to regulate companies’ online activities.

    Preparing for Successful Clinical Advisory Boards: Aim for Clear Objectives, Targeted Recruitment, and Skillful Moderators 2014

    Conducting effective advisory boards relies on several factors, including getting the right group of experts together, asking them the right questions, and guiding the conversation toward useful solutions. All of these goals can be achieved via thorough preparation before the meeting even begins. Depending on how companies manage their advisory board activities, in-house and external groups must coordinate some of these efforts. All involved parties, however, should understand the importance of laying the groundwork for these meetings. Even as parts of the pharma industry consider the move toward online solutions for their advisory board needs, many of these steps will remain part of the process of setting up meetings.

    Accessing the Inaccessible: Strategies for Rebuilding the Relationship Between Pharma and Physicians 2014

    Recently, pharma has been caught in between increasingly strict regulations and physicians’ declining interest in hearing what reps have to say. These forces are changing the pharmaceutical industry as a whole. In response, sales teams must adapt to an entirely new environment yet are hesitant to place too much hope upon any unproven strategy. Unfortunately, however, there is no way to sufficiently face the challenges that the new marketplace brings without some level of major change.

    Divesting Non-Core Products Offers Pharma a Fresh Approach to LCM 2014

    Divestitures offer a creative approach to LCM strategy for drugs in clinical development through patent protection. The traditional solutions to retaining market share, investing in trials to develop reformulations or paying for years of battling patent rights in courts, are expensive. Instead, some companies have decided to simply divest brands, therapeutic area portfolios or entire divisions. Divesting products still in Discovery proves especially lucrative. It also gives pharma companies the opportunity to invest more heavily in their core brands. Companies are more and more trying this approach, and thus the age of drug acquisitions by large pharma is quickly being replaced by an age of portfolio pruning and streamlining.